Core Viewpoint - The company, Chaoyan Co., Ltd., has experienced a decline in stock performance and financial metrics, indicating potential challenges in its operational performance and market position [1][2]. Financial Performance - As of September 30, 2025, Chaoyan Co., Ltd. reported a revenue of 254 million yuan, a year-on-year decrease of 2.90% [2]. - The net profit attributable to shareholders for the same period was approximately 88.94 million yuan, reflecting a decline of 3.66% year-on-year [2]. - Cumulative cash dividends distributed since the company's A-share listing amount to approximately 43.69 million yuan [2]. Stock and Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per shareholder increased by 39.99% to 3,438 shares [2]. - The total financing balance for Chaoyan Co., Ltd. is approximately 96.65 million yuan, accounting for 6.63% of its market capitalization [1]. Institutional Holdings - The largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which decreased by 388,200 shares compared to the previous period [3]. - New institutional shareholders include Yuanxin Yongfeng Medical Health A, holding 650,100 shares, and Medical Device ETF, holding 350,100 shares [3]. - Other notable changes include Hong Kong Central Clearing Limited increasing its holdings by 62,000 shares to 532,000 shares [3].
超研股份10月29日获融资买入342.12万元，融资余额9665.46万元